Hans Wigzell

Founder at Affibody Medical AB

Hans Wigzell

Hans Wigzell

Founder at Affibody Medical AB

Overview
Career Highlights

Affibody Medical AB

RelSci Relationships

1504

Number of Boards

26

Birthday

1939

Age

81

Number of Awards

2

Relationships
RelSci Relationships are individuals Hans Wigzell likely has professional access to. A relationship does not necessarily indicate a personal connection.

Executive Chairman at Swedish Orphan Biovitrum AB

Relationship likelihood: Strong

Chairman at Ferrosan ApS

Relationship likelihood: Strong

Professional at Valneva SE

Relationship likelihood: Strong

President & Chief Executive Officer at RaySearch Laboratories AB

Relationship likelihood: Strong

Founding Partner & Chief Investment Officer at Rhenman & Partners Asset Management AB

Relationship likelihood: Strong

Founding Partner at Rhenman & Partners Asset Management AB

Relationship likelihood: Strong

Founding Partner at Rhenman & Partners Asset Management AB

Relationship likelihood: Strong

President & Chief Executive Officer at Sarepta Therapeutics, Inc.

Relationship likelihood: Strong

Founder at BioArctic AB

Relationship likelihood: Strong

Professional at Valneva SE

Relationship likelihood: Strong

Paths to Hans Wigzell
Potential Connections via
Relationship Science
You
Hans Wigzell
Founder at Affibody Medical AB
Education
MD
Class of 1967

Karolinska Institutet is a medical university in Solna within the Stockholm urban area, Sweden, and one of Europe's largest and most prestigious medical universities. It was founded in 1810 on Kungsholmen on the west side of Stockholm; the main campus was relocated decades later to Solna, just outside Stockholm. A second campus was established more recently in Flemingsberg, Huddinge, south of Stockholm.

Memberships
Member
Current

Founded in 1780, the American Academy of Arts and Sciences is an independent policy research center that conducts multidisciplinary studies of complex and emerging problems. The Academy’s elected members are leaders in the academic disciplines, the arts, business, and public affairs. With a current membership of 4,000 American Fellows and 600 Foreign Honorary Members, the Academy has four major goals: Promoting service and study through analysis of critical social and intellectual issues and the development of practical policy alternatives; Fostering public engagement and the exchange of ideas with meetings, conferences, and symposia bringing diverse perspectives to the examination of issues of common concern; Mentoring a new generation of scholars and thinkers through the Visiting Scholars Program and Hellman Fellowship Program; Honoring excellence by electing to membership men and women in a broad range of disciplines and professions. Click here to learn about our new members. The Academy's headquarters are in Cambridge, Massachusetts. With its geographically diverse membership, it conducts activities in this country and abroad

Member
Current

Founded in 1919 and was the first engineering science academy in the world.

Career History
Founder
1998 - Prior

Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden.

Dean
1995 - 2003

Karolinska Institutet is a medical university in Solna within the Stockholm urban area, Sweden, and one of Europe's largest and most prestigious medical universities. It was founded in 1810 on Kungsholmen on the west side of Stockholm; the main campus was relocated decades later to Solna, just outside Stockholm. A second campus was established more recently in Flemingsberg, Huddinge, south of Stockholm.

General Director
1987 - 1993
Boards & Committees
Member, Board of Directors
2006 - Current

KD's investment approach aims to transfer life sciences innovations into commercial applications while improving human health. They are an early investor with the objective of being the lead investor. They generally maintain a significant position in their portfolio firms until exit. They endeavor to rapidly build value in high risk opportunities.Among key investment criteria, they seek innovations, either pharmaceutical or medical technology applications, which address unmet medical needs. KD looks for opportunities displaying a strong IP position, preferably with a patent application, as well as unique skills or processes.KD works closely with regional Nordic academic and research institutions. Their deal flow agreement with Karolinska Institutet Innovations ensures priority access of promising opportunities at a very early stage. In addition to capital infusion, the firm supports their investments through business development expertise, technical specialists and access to their wide-ranging professional network.

Member, General Scientific Advisory Board
Current

BioArctic AB engages in the research and development of modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson's disease. It also develops treatment for complete spinal cord injury. The company was founded by Lars Gunnar Lannfelt and Pär Lars Gellerfors on January 24, 2003 and is headquartered in Stockholm, Sweden.

Director
Current
Chairman
Current

The Stockholm School of Entrepreneurship is recognised around the world as a leading academic facility in the area of innovation and entrepreneurship. The school utilises the exciting and diverse academic environments of its member institutions (KI, KTH, SSE, Stockholm University and Konstfack), gathering their innovative and entrepreneurial competencies all under one roof in a joint education programme.

Director
Prior

Sage Bionetworks is a strategic research organization with a mission to coordinate and link academic and commercial biomedical researchers, patients and citizens through a Commons that represents a new paradigm for genomics intellectual property, researcher cooperation and contributor evolved resources. This mission has several interdependent themes, including: conducting research on network models of disease; building the computational platform for the Commons; and activating public engagement.

Investments
Details Hidden

Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden.

Public Holdings
Restricted data only for RelSci Professional users.
Awards & Honors
University of Turku
Università degli Studi di Roma Tor Vergata
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Hans Wigzell. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Hans Wigzell's profile does not indicate a business or promotional relationship of any kind between RelSci and Hans Wigzell.